Chugai Pharmaceutical Co Ltd (TSE:4519, Financial) is set to release its Q3 2024 earnings on Oct 25, 2024. The consensus estimate for Q3 2024 revenue is 276.20 billion, and the earnings are expected to come in at 57.37 per share. The full year 2024's revenue is expected to be $1.12 billion and the earnings are expected to be $224.14 per share. More detailed estimate data can be found on the Forecast page.
Chugai Pharmaceutical Co Ltd (TSE:4519, Financial) Estimate Trends
Over the past 90 days, revenue estimates for Chugai Pharmaceutical Co Ltd (TSE:4519) for the full year 2024 have increased from $1.09 billion to $1.12 billion, and for 2025, they have risen from $1.14 billion to $1.15 billion. Similarly, earnings estimates have risen from $211.16 per share to $224.14 per share for the full year 2024, and from $226.05 per share to $236.18 per share for 2025.
Chugai Pharmaceutical Co Ltd (TSE:4519, Financial) Reported History
In the previous quarter of 2024-06-30, Chugai Pharmaceutical Co Ltd's (TSE:4519) actual revenue was 315.91 billion, which beat analysts' revenue expectations of 274.12 billion by 15.24%. Chugai Pharmaceutical Co Ltd's (TSE:4519) actual earnings were $67.98 per share, which beat analysts' earnings expectations of $55.46 per share by 22.57%. After releasing the results, Chugai Pharmaceutical Co Ltd (TSE:4519) was down by -2.21% in one day.
Chugai Pharmaceutical Co Ltd (TSE:4519, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 12 analysts, the average target price for Chugai Pharmaceutical Co Ltd (TSE:4519) is $6,945.83 with a high estimate of $8,500 and a low estimate of $4,500. The average target implies an upside of 0.81% from the current price of $6,890.
Based on GuruFocus estimates, the estimated GF Value for Chugai Pharmaceutical Co Ltd (TSE:4519, Financial) in one year is $4,192.61, suggesting a downside of -39.15% from the current price of $6,890.
Based on the consensus recommendation from 14 brokerage firms, Chugai Pharmaceutical Co Ltd's (TSE:4519, Financial) average brokerage recommendation is currently 2.2, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
